Works by Sundby Palle, Mads
Results: 3
Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 710, doi. 10.1111/dom.16065
- By:
- Publication type:
- Article
Liraglutide as add‐on to sodium‐glucose co‐transporter‐2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind, placebo‐controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 6, p. 929, doi. 10.1111/dom.13978
- By:
- Publication type:
- Article
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2021, v. 54, n. 9, p. 1150, doi. 10.1111/apt.16608
- By:
- Publication type:
- Article